Clinical and economic burden of invasive fungal diseases in Europe: Focus on pre-emptive and empirical treatment of Aspergillus and Candida species

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 33, Issue 1, 2014, Pages 7-21

  Drgona, L ^a   Khachatryan, A ^b   Stephens, J ^b   Charbonneau, C ^c   Kantecki, M ^c   Haider, S ^d   Barnes, R ^e  

^a Faculty of Natural Sciences   (Slovakia)

^b PHARMERIT INTERNATIONAL   (United States)

^c PFIZER INC   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^e CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CLINICAL LABORATORY TECHNIQUES; EARLY DIAGNOSIS; EUROPE; HUMANS;

EID: 84895064119     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-013-1944-3     Document Type: Review

References (92)

1. Menzin J, Meyers JL, Friedman M, Perfect JR, Langston AA, Danna RP, Papadopoulos G (2009) Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm 66:1711-1717
2. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813-1821
3. Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L, Paul M (2007) Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 25:5471-5489
4. Segal BH, Freifeld AG, Baden LR, Brown AE, Casper C, Dubberke E, Gelfand M, Greene JN, Ison MG, Ito JI, Karp JE, Kaul DR, King E, Mackler E, Marcucci G, Montoya JG, Engemann AM, Rolston K, The AS (2008) Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 6:122-174
5. Cornely OA, Böhme A, Buchheidt D, Einsele H, Heinz WJ, Karthaus M, Krause SW, Krüger W, Maschmeyer G, Penack O, Ritter J, Ruhnke M, Sandherr M, Sieniawski M, Vehreschild JJ, Wolf HH, Ullmann AJ (2009) Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 94:113-122
6. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF; Infectious Diseases Society of America (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327-360
7. Freemantle N, Tharmanathan P, Herbrecht R (2011) Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease. J Antimicrob Chemother 66(Suppl 1):i25-i35
8. Herbrecht R, Berceanu A (2008) Beta-D-glucan detection test: a step toward preemptive therapy for fungal infections in leukemic patients? Clin Infect Dis 46:886-889
9. Steinbach WJ, Juvvadi PR, Fortwendel JR, Rogg LE (2011) Newer combination antifungal therapies for invasive aspergillosis. Med Mycol 49(Suppl 1):S77-S81
10. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD; Infectious Diseases Society of America (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503-535
11. Mosquera J, Denning DW (2002) Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 46:556-557
12. Wilson DT, Drew RH, Perfect JR (2009) Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update. Mycopathologia 168:313-327
13. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415
14. Lass-Flörl C, Griff K, Mayr A, Petzer A, Gastl G, Bonatti H, Freund M, Kropshofer G, Dierich MP, Nachbaur D (2005) Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 131:201-207
15. Perkhofer S, Lass-Flörl C, Hell M, Russ G, Krause R, Hönigl M, Geltner C, Auberger J, Gastl G, Mitterbauer M, Willinger B, Knöbl P, Resch G, Waldner R, Makrai A, Hartmann G, Girschikofsky M, Greil R (2010) The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. Int J Antimicrob Agents 36:531-536
16. Presterl E, Daxböck F, Graninger W, Willinger B (2007) Changing pattern of candidaemia 2001-2006 and use of antifungal therapy at the University Hospital of Vienna, Austria. Clin Microbiol Infect 13:1072-1076
17. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, Van Eldere J (2005) Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41:1242-1250
18. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E (2004) Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 170:621-625
19. Van Campenhout H, Marbaix S, Derde MP, Annemans L (2008) Voriconazole treatment of invasive aspergillosis: real-world versus health-economic model results. Clin Drug Investig 28:509-521
20. Vandewoude K, Blot S, Benoit D, Depuydt P, Vogelaers D, Colardyn F (2004) Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality. Acta Clin Belg 59:251-257
21. Anttila VJ, Salonen J, Ylipalosaari P, Koivula I, Riikonen P, Nikoskelainen J (2007) A retrospective nationwide case study on the use of a new antifungal agent: patients treated with caspofungin during 2001-2004 in Finland. Clin Microbiol Infect 13:606-612
22. Jantunen E, Salonen J, Juvonen E, Koivunen E, Siitonen T, Lehtinen T, Kuittinen O, Leppä S, Anttila VJ, Itälä M, Wiklund T, Remes K, Nousiainen T (2004) Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. Eur J Haematol 73:174-178
23. Bénet T, Nicolle MC, Thiebaut A, Piens MA, Nicolini FE, Thomas X, Picot S, Michallet M, Vanhems P (2007) Reduction of invasive aspergillosis incidence among immunocompromised patients after control of environmental exposure. Clin Infect Dis 45:682-686
24. Cordonnier C, Ribaud P, Herbrecht R, Milpied N, Valteau-Couanet D, Morgan C, Wade A; Société Française de Greffe de Moelle et de Thérapie Cellulaire (2006) Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 42:955-963
25. Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, Dhédin N, Isnard F, Ades L, Kuhnowski F, Foulet F, Kuentz M, Maison P, Bretagne S, Schwarzinger M (2009) Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 48:1042-1051
26. Cornet M, Fleury L, Maslo C, Bernard JF, Brücker G; Invasive Aspergillosis Surveillance Network of the Assistance Publique-Hôpitaux de Paris (2002) Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect 51:288-296
27. Fourneret-Vivier A, Lebeau B, Mallaret MR, Brenier-Pinchart MP, Brion JP, Pinel C, Garban F, Pison C, Hamidfar R, Plantaz D, Pelloux H, Grillot R (2006) Hospital-wide prospective mandatory surveillance of invasive aspergillosis in a French teaching hospital (2000-2002). J Hosp Infect 62:22-28
28. Gallien S, Fournier S, Porcher R, Bottero J, Ribaud P, Sulahian A, Socié G, Molina JM (2008) Therapeutic outcome and prognostic factors of invasive aspergillosis in an infectious disease department: a review of 34 cases. Infection 36:533-538
29. Gangneux J, DuPont B, Michalet M, Herbrecht R, Ribaud P, Caillot D, Moreau P, Berger P, Lafuma A (2008) Associated medical consumption and costs during invasive fungal infection in acute myeloblastic leukemia patients in France. Abstract presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America, Washington, DC, USA, October 25-28 2008
30. Herbrecht R, Cordonnier C, Gangneux J, Caillot D, Auvrignon A, Thiebaut A, Gorin N, Brethon B, Michallet M., Fisher A, Bertrand Y, Preziosi P, Ruiz F (2010) Management and outcomes of invasive fungal diseases (IFD) in patients with hematological malignancies: a French Cohort study. Abstract presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, USA, September 12-15 2010
31. Lafaurie M, Lapalu J, Raffoux E, Breton B, Lacroix C, Socié G, Porcher R, Ribaud P, Touratier S, Molina JM (2010) High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. Clin Microbiol Infect 16:1191-1196
32. Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, Carlet J, Reynes J, Rosenheim M, Regnier B, Lortholary O; AmarCand Study Group (2009) Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 37:1612-1618
33. Lortholary O, Charlemagne A, Bastides F, Chevalier P, Datry A, Gonzalves MF, Michel G, Tilleul P, Veber B, Herbrecht R (2004) A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998-1999. J Antimicrob Chemother 54:456-464
34. Michallet M, Benet T, Kraghel S, Sobh M, El Hamri M, Cannas G, Nicolini F, Labussiere H, Duscastelle-Lepretre S, Barraco F, Chelghoum Y, Thomas X, Nicoll M, Bienvenu A, Persat F, Vanhems P (2010) Invasive aspergillosis: a new important risk factor on short and long-term survival of AML patients. Haematologica 95:30
35. Berger K, Cornely O, Hoppe-Tichy T, Kiehl M, Knoth H, Rieger C, Thalheimer M, Schuler U, Ullmann A, Osterman H (2008) Invasive fungal infection (IFI) in patients with acute myelogenous (AML) or myslodysplastic syndrome (MDS) - treatment cost from hospital perspective. Abstract presented at the International Society for Pharmacoeconomics and Outcome Research 11th Annual European Congress, Athens, Greece, November 8-11 2008
36. Boehme A, Atta J, Mousset S, Steffan B, Serve H, Hoelzer D, Shlaen R, Ehlken B, Bug G (2010) Change of antifungal treatment patterns and associated costs in patients with acute myelogenous leukemia (AML) after chemotherapy in a German hospital from 2004 to 2006. Abstract presented at the International Society for Pharmacoeconomics and Outcome Research 13th Annual European Congress, Prague, Czech Republic, November 6-9 2010
37. Cornely OA, Sidhu M, Odeyemi I, van Engen AK, van der Waal JM, Schoeman O (2008) Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin 24:1743-1753
38. Hahn-Ast C, Glasmacher A, Mückter S, Schmitz A, Kraemer A, Marklein G, Brossart P, von Lilienfeld-Toal M (2010) Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother 65:761-768
39. Hebart H, Klingspor L, Klingebiel T, Loeffler J, Tollemar J, Ljungman P, Wandt H, Schaefer-Eckart K, Dornbusch HJ, Meisner C, Engel C, Stenger N, Mayer T, Ringden O, Einsele H (2009) A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplant 43:553-561
40. Jansen JP, Kern WV, Cornely OA, Karthaus M, Ruhnke M, Ullmann AJ, Resch A (2006) Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health 9:12-23
41. Kovalevskaya E, Hummel M, Spiess B, Buchheidt D (2008) Investigating non-blood specimens of neutropenic patients with hematological malignancies with a nested Aspergillus PCR assay: clinical results. Abstract presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America, Washington, DC, USA, October 25-28 2008
42. Lehrnbecher T, Frank C, Engels K, Kriener S, Groll AH, Schwabe D (2010) Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 61:259-265
43. Schwesinger G, Junghans D, Schröder G, Bernhardt H, Knoke M (2005) Candidosis and aspergillosis as autopsy findings from 1994 to 2003. Mycoses 48:176-180
44. Spiliopoulou A, Vamvacopoulou S, Bartzavali C, Picoula L, Anastassiou L, Christofidon M (2009) Candidemia: retrospective analysis of eleven year experience. Poster presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Conference, San Francisco, CA, USA, September 12-14 2012
45. Dimopoulos G, Ntziora F, Rachiotis G, Armaganidis A, Falagas ME (2008) Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg 106:523-529
46. Roilides E, Farmaki E, Evdoridou J, Dotis J, Hatziioannidis E, Tsivitanidou M, Bibashi E, Filioti I, Sofianou D, Gil-Lamaignere C, Mueller FM, Kremenopoulos G (2004) Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates. Eur J Clin Microbiol Infect Dis 23:745-750
47. Boo TW, O'Reilly B, O'Leary J, Cryan B (2005) Candidaemia in an Irish tertiary referral hospital: epidemiology and prognostic factors. Mycoses 48:251-259
48. Scanlon N, Jaura A, Fraher M, Collins C, Marsh B, McWade R, Hannan M (2008) A change in epidemiology of fungal infections in ICU patients: the impact of antifungal therapy. Abstract presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America, Washington, DC, USA, October 25-28 2008
49. Bedini A, Venturelli C, Mussini C, Guaraldi G, Codeluppi M, Borghi V, Rumpianesi F, Barchiesi F, Esposito R (2006) Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. Clin Microbiol Infect 12:75-80
50. Girmenia C, Pizzarelli G, Cristini F, Barchiesi F, Spreghini E, Scalise G, Martino P (2006) Candida guilliermondii fungemia in patients with hematologic malignancies. J Clin Microbiol 44:2458-2464
51. Girmenia C, Micozzi A, Gentile G, Santilli S, Arleo E, Cardarelli L, Capria S, Minotti C, Cartoni C, Brocchieri S, Guerrisi V, Meloni G, Foà R, Martino P (2010) Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol 28:667-674
52. Lequaglie C (2002) Liposomal amphotericin B (AmBisome): efficacy and safety of low-dose therapy in pulmonary fungal infections. J Antimicrob Chemother 49(Suppl 1):49-50
53. Libanore M, Prini E, Mazzetti M, Barchi E, Raise E, Gritti FM, Bonazzi L, Ghinelli F (2002) Invasive aspergillosis in Italian AIDS patients. Infection 30:341-345
54. Pagano L, Caira M, Nosari A, Van Lint MT, Candoni A, Offidani M, Aloisi T, Irrera G, Bonini A, Picardi M, Caramatti C, Invernizzi R, Mattei D, Melillo L, de Waure C, Reddiconto G, Fianchi L, Valentini CG, Girmenia C, Leone G, Aversa F (2007) Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study - Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 45:1161-1170
55. Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, Pastore D, Stanzani M, Cattaneo C, Fanci R, Caramatti C, Rossini F, Luppi M, Potenza L, Ferrara F, Mitra ME, Fadda RM, Invernizzi R, Aloisi T, Picardi M, Bonini A, Vacca A, Chierichini A, Melillo L, de Waure C, Fianchi L, Riva M, Leone G, Aversa F, Nosari A (2010) Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 95:644-650
56. Posteraro B, Sanguinetti M, Boccia S, De Feo E, La Sorda M, Tana M, Tirone C, Aurilia C, Vendettuoli V, Fadda G, Romagnoli C, Vento G (2010) Early mannan detection in bronchoalveolar lavage fluid with preemptive treatment reduces the incidence of invasive Candida infections in preterm infants. Pediatr Infect Dis J 29:844-848
57. Riva M, Nosari A, Rizio A, Molteni A, Vanelli C, Gabutti C, Nador G, Morra E (2008) In high risk acute leukemia patients early antifungal therapy (EAT) improves the outcome of invasive mould infections. Abstract presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America, Washington, DC, USA, October 25-28 2008
58. Stam WB, O'Sullivan AK, Rijnders B, Lugtenburg E, Span LF, Janssen JJ, Jansen JP (2008) Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol 81:467-474
59. Ament AJ, Hübben MW, Verweij PE, de Groot R, Warris A, Donnelly JP, van't Wout J, Severens JL (2007) Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach. J Antimicrob Chemother 60:385-393
60. Jansen JP, Meis JF, Blijlevens NM, van't Wout JW (2005) Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Curr Med Res Opin 21:1535-1546
61. Slobbe L, Polinder S, Doorduijn JK, Lugtenburg PJ, el Barzouhi A, Steyerberg EW, Rijnders BJ (2008) Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis 47:1507-1512
62. Odds FC, Hanson MF, Davidson AD, Jacobsen MD, Wright P, Whyte JA, Gow NA, Jones BL (2007) One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol 56:1066-1075
63. Allam MF, Del Castillo AS, Díaz-Molina C, Navajas RF (2002) Invasive pulmonary aspergillosis: identification of risk factors. Scand J Infect Dis 34:819-822
64. Almirante B, Rodríguez D, Cuenca-Estrella M, Almela M, Sanchez F, Ayats J, Alonso-Tarres C, Rodriguez-Tudela JL, Pahissa A (2006) Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 44:1681-1685
65. Bouza E, Guinea J, Peláez T, Pérez-Molina J, Alcalá L, Muñoz P (2005) Workload due to Aspergillus fumigatus and significance of the organism in the microbiology laboratory of a general hospital. J Clin Microbiol 43:2075-2079
66. Cisterna R, Ezpeleta G, Telleria O (2010) A multicenter antifungal susceptibility study of invasive Candida spp. infection in Spain. Abstract presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, USA, September 12-15 2010
67. Martin-Pena A, Gil-Navarro M, Aguilar-Guisado M, Espigado I, Cordero E, Pachon J, Cisneros J (2010) Cost-effectiveness study of empirical antifungal strategies in patients with persistent febrile neutropenia. Abstract presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, USA, September 12-15 2010
68. Domínguez-Gil A, Martín I, García Vargas M, Del Castillo A, Díaz S, Sánchez C (2007) Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain. Clin Drug Investig 27:197-205
69. Fortun J, Martin-Davila P, Ros L, Luengo J, Agundez M, Sanchez-Sousa A et al (2009) Impact of epidemiological changes in candidemia on outcome. Abstract presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, September 12-14 2009
70. Garcia M, Marti B, Ferro B (2009) Budget impact analysis of three candins in the treatment of invasive candidiasis in adult non-neutropenic patients in Spain. Abstract presented at the International Society for Pharmacoeconomics and Outcome Research 12th Annual European Congress, Paris, France, October 24-27 2009
71. Garnacho-Montero J, Díaz-Martín A, García-Cabrera E, Ruiz Pérez de Pipaón M, Hernández-Caballero C, Aznar-Martín J, Cisneros JM, Ortiz-Leyba C (2010) Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother 54:3149-3154
72. Guinea J, Jenson J, Torres-Narbona M, Gijon Pelaez T, Munoz P, Bouza E (2008) Chronic obstructive pulmonary disease (COPD) is currently the most predisposing condition to invasive aspergillosis. Abstract presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America, Washington, DC, USA, October 25-28 2008
73. Guinea J, Torres-Narbona M, Gijon Pelaez T, Munoz P, Bouza E (2008) Invasive pulmonary aspergillosis (IPA) in patients with COPD: a description of 57 cases collected in a single tertiary hospital (1999-2008). Abstract presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy/ Infectious Diseases Society of America, Washington, DC, USA, October 25-28 2008
74. Aguilar-Guisado M, Espigado I, Cordero E, Noguer M, Parody R, Pachón J, Cisneros JM (2010) Empirical antifungal therapy in selected patients with persistent febrile neutropenia. Bone Marrow Transplant 45:159-164
75. Ortega M, Alemla M, Soriano A, Marco F, Martinez J, Pitart C, Nicolau C, Mensa J (2010) Analysis of 540 episodes of Candida bloodstream infection isolated in a single institution from Barcelona: impact of treatment in outcome. Abstract presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, USA, September 12-15 2010
76. Rubio PM, Sevilla J, González-Vicent M, Lassaletta A, Cuenca-Estrella M, Díaz MA, Riesco S, Madero L (2009) Increasing incidence of invasive aspergillosis in pediatric hematology oncology patients over the last decade: a retrospective single centre study. J Pediatr Hematol Oncol 31:642-646
77. Garbino J, Schnetzler G, Roberts C (2005) Invasive aspergillosis: is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand? Swiss Med Wkly 135:624-630
78. Weisser M, Rausch C, Droll A, Simcock M, Sendi P, Steffen I, Buitrago C, Sonnet S, Gratwohl A, Passweg J, Fluckiger U (2005) Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies. Clin Infect Dis 41:1143-1149
79. Barnes RA, White PL, Bygrave C, Evans N, Healy B, Kell J (2009) Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J Clin Pathol 62:64-69
80. Bruynesteyn K, Gant V, McKenzie C, Pagliuca T, Poynton C, Kumar RN, Jansen JP (2007) A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol 78:532-539
81. Clerihew L, Lamagni TL, Brocklehurst P, McGuire W (2007) Candida parapsilosis infection in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 92:F127-F129
82. Dignan FL, Evans SO, Ethell ME, Shaw BE, Davies FE, Dearden CE, Treleaven JG, Riley UB, Morgan GJ, Potter MN (2009) An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality. Bone Marrow Transplant 44:51-56
83. Edi-Osagie NE, Emmerson AJ (2005) Seasonality of invasive Candida infection in neonates. Acta Paediatr 94:72-74
84. El-Masry FA, Neal TJ, Subhedar NV (2002) Risk factors for invasive fungal infection in neonates. Acta Paediatr 91:198-202
85. Schelenz S, Barnes RA, Kibbler CC, Jones BL, Denning DW (2009) Standards of care for patients with invasive fungal infections within the United Kingdom: a national audit. J Infect 58:145-153
86. Sidhu MK, van Engen AK, Kleintjens J, Schoeman O, Palazzo M (2009) Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK. Curr Med Res Opin 25:2049-2059
87. Lortholary O, Ascioglu S, Moreau P, Herbrecht R, Marinus A, Casassus P, De Pauw B, Denning DW (2000) Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Intergroupe Français du Myélome. Clin Infect Dis 30:41-46
88. Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, Biraghi E, Canton E, Zimmermann K, Seaton S, Grillot R; ECMM Working Group on Candidaemia (2004) Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 23:317-322
89. Drgona L, Trupl J, Hupkova H (2010) Clinical analysis of 92 patients with fungaemia - data from national survey in Slovak. Poster presented at the 14th International Congress on Infectious Diseases, Miami, FL, USA, March 9-12 2010
90. Drgona L, Kotulova D, Trupl J, Kunova A, Hupkova H, Lisalova M, Marcek T (2011) Trends of candidaemia in Slovakia - a comparison of two consecutive, prospective studies. Poster presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, May 7-10 2011
91. Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S; European Conference on Infections in Leukemia (ECIL) Laboratory Working Groups (2012) ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant 47:846-854
92. Cuenca-Estrella M, Verweij PE, Arendrup MC, Arikan-Akdagli S, Bille J, Donnelly JP, Jensen HE, Lass-Flörl C, Richardson MD, Akova M, Bassetti M, Calandra T, Castagnola E, Cornely OA, Garbino J, Groll AH, Herbrecht R, Hope WW, Kullberg BJ, Lortholary O, Meersseman W, Petrikkos G, Roilides E, Viscoli C, Ullmann AJ; ESCMID Fungal Infection Study Group (2012) ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 18(Suppl 7):9-18